<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03050268</url>
  </required_header>
  <id_info>
    <org_study_id>SJFAMILY</org_study_id>
    <nct_id>NCT03050268</nct_id>
  </id_info>
  <brief_title>Familial Investigations of Childhood Cancer Predisposition</brief_title>
  <acronym>SJFAMILY</acronym>
  <official_title>Familial Investigations of Childhood Cancer Predisposition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NOTE: This is a research study and is not meant to be a substitute for clinical genetic
      testing. Families may never receive results from the study or may receive results many years
      from the time they enroll. If you are interested in clinical testing please consider seeing a
      local genetic counselor or other genetics professional. If you have already had clinical
      genetic testing and meet eligibility criteria for this study as shown in the Eligibility
      Section, you may enroll regardless of the results of your clinical genetic testing.

      While it is well recognized that hereditary factors contribute to the development of a subset
      of human cancers, the cause for many cancers remains unknown. The application of next
      generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary
      cancer predisposition. Currently, more than 100 cancer predisposing genes have been
      identified, and it is now estimated that approximately 10% of all cancer patients have an
      underlying genetic predisposition.

      The purpose of this protocol is to identify novel cancer predisposing genes and/or genetic
      variants. For this study, the investigators will establish a Data Registry linked to a
      Repository of biological samples. Health information, blood samples and occasionally leftover
      tumor samples will be collected from individuals with familial cancer. The investigators will
      use NGS approaches to find changes in genes that may be important in the development of
      familial cancer. The information gained from this study may provide new and better ways to
      diagnose and care for people with hereditary cancer.

      PRIMARY OBJECTIVE:

        -  Establish a registry of families with clustering of cancer in which clinical data are
           linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues
           from the proband and other family members.

      SECONDARY OBJECTIVE:

        -  Identify novel cancer predisposing genes and/or genetic variants in families with
           clustering of cancer for which the underlying genetic basis is unknown.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the study, blood samples will be obtained from participants, as well as medical and
      family histories. When possible, leftover tumor samples will also be collected. If
      participants agree to be re-contacted in the future, they will be asked about once each year
      to update their health information and family history.

      A blood sample will be drawn at St. Jude or at a convenient place of the participant's
      choice. Blood will be stored in the St. Jude Biorepository. The DNA of the samples will be
      studied to determine if there are changes in specific genes that might explain the cancers in
      the participant or their family members. When available, and if consent is given by the
      participant, previously collected and stored leftover tumor samples, bone marrow samples or
      stored DNA may be analyzed.

      Genetic variants of interest include: 1) mutations in known genes that may have escaped
      detection through prior clinical genetic testing; 2) coding mutations predicted to disrupt
      protein function, particularly in genes and pathways known to be associated with cancer; 3)
      potential mutations in regulatory regions of the genome, as predicted by epigenetic studies.
      In some cases, individuals with known predisposing mutations exhibit milder, more severe or
      atypical phenotypes. Family members who harbor a predisposing mutation but are discordant for
      a cancer phenotype will be selected for cellular and genetic studies. These will include DNA
      sequencing and possibly also creation and analysis of induce pluripotent stem cells (iPSC),
      transcriptome or epigenetic analysis.

      All samples will be identified by a code after removal of all personal identifiable
      information. Samples will remain in the repository for current and future study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2037</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2037</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of novel cancer predisposing genes</measure>
    <time_frame>Up to 20 years following study activation</time_frame>
    <description>Probands and cancer affected and unaffected relatives from selected families will be sequenced using Whole Genome Sequencing (WGS) or possibly Whole Exome Sequencing (WES) and analyzed to identify new predisposing genetic variants that co-segregate with the tumor phenotype. Data will be analyzed using annotation and filtering strategies to identify potentially deleterious germline mutations that co-segregate with disease.</description>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Adenomatous Polyposis</condition>
  <condition>Adrenocortical Carcinoma</condition>
  <condition>AML</condition>
  <condition>BAP1 Tumor Predisposition Syndrome</condition>
  <condition>Carney Complex</condition>
  <condition>Choroid Plexus Carcinoma</condition>
  <condition>Constitutional Mismatch Repair Deficiency Syndrome</condition>
  <condition>Diamond-Blackfan Anemia</condition>
  <condition>DICER1 Syndrome</condition>
  <condition>Dyskeratosis Congenita</condition>
  <condition>Emberger Syndrome</condition>
  <condition>Familial Acute Myeloid Leukemia</condition>
  <condition>Familial Adenomatous Polyposis</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Familial Cancer</condition>
  <condition>Familial Wilms Tumor</condition>
  <condition>Familial Neuroblastoma</condition>
  <condition>GIST</condition>
  <condition>Hereditary Breast and Ovarian Cancer</condition>
  <condition>Hereditary Paraganglioma-Pheochromocytoma Syndrome</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Juvenile Polyposis</condition>
  <condition>Li-Fraumeni Syndrome</condition>
  <condition>Lynch Syndrome</condition>
  <condition>MDS</condition>
  <condition>Melanoma Syndrome</condition>
  <condition>Multiple Endocrine Neoplasia Type 1</condition>
  <condition>Multiple Endocrine Neoplasia Type 2</condition>
  <condition>Neuroblastoma</condition>
  <condition>Neurofibromatosis Type 1</condition>
  <condition>Neurofibromatosis Type II</condition>
  <condition>Nevoid Basal Cell Carcinoma Syndrome</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Noonan Syndrome and Other Rasopathy</condition>
  <condition>Overgrowth Syndromes</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Peutz-Jeghers Syndrome</condition>
  <condition>Pheochromocytoma/Paraganglioma</condition>
  <condition>PTEN Hamartoma Tumor Syndrome</condition>
  <condition>Retinoblastoma</condition>
  <condition>Rhabdoid Tumor Predisposition Syndrome</condition>
  <condition>Rhabdomyosarcoma</condition>
  <condition>Rothmund-Thomson Syndrome</condition>
  <condition>Tuberous Sclerosis</condition>
  <condition>Von Hippel-Lindau Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples and leftover tumor samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with cancer and their family members who meet the eligibility criteria shown
        below.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        NOTE: This is a research study and is not meant to be a substitute for clinical genetic
        testing. Families may never receive results from the study or may receive results many
        years from the time they enroll. If you are interested in clinical testing please consider
        seeing a local genetic counselor or other genetics professional. If you have already had
        clinical genetic testing and meet eligibility criteria for this study as shown below, you
        may enroll regardless of the results of your clinical genetic testing.

        DEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL:

        In this protocol, the definition of &quot;Familial Cancer&quot; is met if any of the following is
        present:

          -  An individual with a history of cancer diagnosed under 26 years of age who has at
             least one first, second or third degree relative with a history of cancer diagnosed
             under 51 years of age; OR

          -  An individual who has been diagnosed with more than one cancer, at least one of which
             was diagnosed under 26 years of age; OR

          -  An individual with a clinical or molecular diagnosis of a known cancer predisposition
             syndrome.

        ยบ Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer
        occurring in adults.

        INCLUSION CRITERIA:

          -  An individual who meets this protocol's definition of &quot;Familial Cancer,&quot; as above.

          -  Biologic relatives of an individual meeting this protocol's definition of &quot;Familial
             Cancer,&quot; who are either affected or unaffected by cancer.

        EXCLUSION CRITERIA:

          -  An inability or unwillingness of the research participant or his/her legally
             authorized representative (LAR) to provide written informed consent.

          -  The participant has received allogeneic bone marrow transplantation and has NO
             germline (cancer-unaffected) DNA stored in a biorepository.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chimene Kesserwan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chimene Kesserwan, MD</last_name>
    <phone>866-278-5833</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynn Harrison, MPA</last_name>
    <phone>866-278-5833</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chimene Kesserwan, MD</last_name>
      <phone>866-278-5833</phone>
      <email>referralinfo@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Chimene Kesserwan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial cancer</keyword>
  <keyword>Genetic predisposition</keyword>
  <keyword>Heritable disease</keyword>
  <keyword>Cancer risk</keyword>
  <keyword>Genome analysis</keyword>
  <keyword>Genetic modifiers</keyword>
  <keyword>Next generation sequencing (NGS)</keyword>
  <keyword>Genetic counseling</keyword>
  <keyword>DNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
    <mesh_term>Retinoblastoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
    <mesh_term>Multiple Endocrine Neoplasia</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
    <mesh_term>Von Hippel-Lindau Disease</mesh_term>
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
    <mesh_term>Noonan Syndrome</mesh_term>
    <mesh_term>Li-Fraumeni Syndrome</mesh_term>
    <mesh_term>Dyskeratosis Congenita</mesh_term>
    <mesh_term>Peutz-Jeghers Syndrome</mesh_term>
    <mesh_term>Basal Cell Nevus Syndrome</mesh_term>
    <mesh_term>Hamartoma</mesh_term>
    <mesh_term>Multiple Endocrine Neoplasia Type 1</mesh_term>
    <mesh_term>Multiple Endocrine Neoplasia Type 2a</mesh_term>
    <mesh_term>Neurofibromatosis 2</mesh_term>
    <mesh_term>Carney Complex</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplastic Syndromes, Hereditary</mesh_term>
    <mesh_term>Hamartoma Syndrome, Multiple</mesh_term>
    <mesh_term>Rothmund-Thomson Syndrome</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

